Levofloxacin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Tuberculosis, Pulmonary
Conditions
Tuberculosis, Pulmonary
Trial Timeline
Jun 1, 2007 → —
NCT ID
NCT00495339About Levofloxacin
Levofloxacin is a approved stage product being developed by Sanofi for Tuberculosis, Pulmonary. The current trial status is completed. This product is registered under clinical trial identifier NCT00495339. Target conditions include Tuberculosis, Pulmonary.
What happened to similar drugs?
2 of 4 similar drugs in Tuberculosis, Pulmonary were approved
Approved (2) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00495339 | Approved | Completed |
| NCT00277511 | Phase 3 | Completed |
Competing Products
20 competing products in Tuberculosis, Pulmonary